{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:22:03Z","timestamp":1790767323070,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"BMS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>\n                    The prognosis of most leukemia patients treated with BCR\u2010ABL tyrosine kinase inhibitors (TKIs) is favorable, and a more precise understanding of serious and potentially irreversible treatment\u2010related toxicities is essential to properly inform treatment choice. Few cases of pulmonary arterial hypertension (PAH) have been reported in patients with leukemia treated with dasatinib, a second\u2010generation BCR\u2010ABL TKI. To better understand characteristics and outcomes of dasatinib\u2010treated patients with PAH, all clinical cases of PAH confirmed by right\u2010heart catheterization in the Bristol\u2010Myers Squibb pharmacovigilance database (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200941), including 22 previously unpublished cases, were examined for previous treatments for leukemia, patient characteristics, time to PAH onset, and outcomes. Our analysis shows that compared with PAH due to other etiologies, dasatinib\u2010related PAH is atypical, in that it is associated with partial to complete reversibility upon treatment discontinuation. The incidence of dasatinib\u2010related PAH appears to be low. Most PAH cases were observed in patients who had received prior treatments for leukemia. No specific patient attributes appear to be associated with an increased risk of developing PAH while receiving dasatinib. Symptoms of PAH in dasatinib\u2010treated leukemia patients should prompt a thorough workup, including consideration of confirmatory right\u2010heart catheterization. In cases of confirmed PAH, dasatinib should be discontinued. Am. J. Hematol. 90:1060\u20131064, 2015. \u00a9 2015 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/ajh.24174","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T19:28:24Z","timestamp":1439926104000},"page":"1060-1064","source":"Crossref","is-referenced-by-count":111,"title":["Clinical features of pulmonary arterial hypertension in patients receiving dasatinib"],"prefix":"10.1002","volume":"90","author":[{"given":"Neil P.","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, San Francisco School of Medicine University of California San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wallis","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Critical Care and Allergy, Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison W.","family":"Farber","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Critical Care and Allergy, Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[{"name":"Santa Croce Hospital Cuneo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mausumee","family":"Guha","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Critical Care and Allergy, Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint\u2010Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Peacock","sequence":"additional","affiliation":[{"name":"Scottish Pulmonary Vascular Unit Glasgow United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Bristol\u2010Myers Squibb Co. Sprycel Prescribing Information. Princeton NJ;2014."},{"key":"e_1_2_6_3_1","unstructured":"Novartis Pharmaceutical Corp. Gleevec Prescribing Information. East Hanover NJ;2015."},{"key":"e_1_2_6_4_1","unstructured":"Novartis Pharmaceutical Corp.Tasigna Prescribing Information. East Hanover NJ;2015."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-11-30"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00154210"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.08.007"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.7472"},{"key":"e_1_2_6_12_1","first-page":"476","article-title":"Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib","volume":"25","author":"Philibert L","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp297"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.004"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092306"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0793"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008411"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02606.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100298"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"e_1_2_6_22_1","unstructured":"Novartis Pharmaceuticals. Efficacy Safety Tolerability and Pharmacokinetics (pk) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH). Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179737 accessed on April 20 2015."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2795"},{"key":"e_1_2_6_24_1","first-page":"342","article-title":"Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma","volume":"34","author":"Ryczek R","year":"2013","journal-title":"Pol Merkur Lekarski"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035913"},{"key":"e_1_2_6_26_1","first-page":"76","article-title":"Reversible pulmonary arterial hypertension as a complication of dasatinib treatment, with efficacious and safe continuation of chronic myeloid leukaemia therapy with nilotinib","volume":"4","author":"Patkowska E","year":"2013","journal-title":"Hematologia"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_6_30_1","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System. US Food and Drug Administration Silver Spring MD. Available at:http:\/\/www.fda.gov\/cder\/aers\/default.htm accessed in April2014."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0227"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00091912"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2008.07.002"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.76.4.350"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24174","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T02:37:24Z","timestamp":1695523044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/ajh.24174"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24174","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}